Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
pertaining
Financial report summary
?Management Discussion
- Research and development costs were approximately $277,000 and $214,000 for the three months ended August 31, 2024 and 2023, respectively. The increase of $63,000 or 29% was due to an increase in personnel costs of $42,000 and facility and equipment costs of $22,000, offset by a decrease of $1,000 of other research and development costs, as a result of additional requests imposed by the Food and Drug Administration.
- General and administrative expenses were approximately $93,000 and $38,000 for the three months ended August 31, 2024 and 2023, respectively. The increase of $55,000 or 144% was due to an increase in other costs of $58,000, pertaining to patents, offset by a decrease in legal and other professional costs of $3,000, as a result of increased reporting requirements from regulatory agencies.
- The Company had net losses of approximately $370,000 and $252,000 for the three months ended August 31, 2024 and 2023, respectively. The increase in the net loss from 2024 to 2023 is primarily due to an overall increase in research and development costs and in general and administrative expenses of the Company as described above.